Beauty Health price target lowered to $2 from $4 at Stifel

Stifel lowered the firm’s price target on Beauty Health to $2 from $4 and keeps a Hold rating on the shares. There is evidence of marginal improvement at Beauty Health as the firm’s survey work had “some encouraging data points.” However, and “more importantly,” the firm struggles to identify the company’s “next act” and Syndeo checks suggest the system still has lingering quality control issues, and a reputational hit, which may weigh on the adoption curve, the analyst tells investors.